Multimodality Characterization of Cancer-Associated Fibroblasts in Tumor Microenvironment and Its Correlation With Ultrasound Shear Wave-Measured Tissue Stiffness in Localized Prostate Cancer

Wael Ageeli1,2, Xinyu Zhang3, Chidozie N. Ogbonnaya1, Susan E. Bray4, Neil M. Kernohan5, Jennifer Wilson5, Chunhui Li6 and Ghulam Nabi1*

1 Division of Imaging Sciences and Technology, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, United Kingdom, 2 Diagnostic Radiology Department, College of Applied Medical Sciences, Jazan University, Jazan, Saudi Arabia, 3 Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, United Kingdom, 4 Tayside Biorepository, Ninewells Hospital & Medical School, University of Dundee, Dundee, United Kingdom, 5 Department of Pathology, Ninewells Hospital, Dundee, United Kingdom, 6 School of Science and Engineering, University of Dundee, Dundee, United Kingdom

Introduction: Growing evidence suggests that the tumor microenvironment (TME) represented by cellular and acellular components plays a key role in the multistep process of metastases and response to therapies. However, imaging and molecular characterization of the TME in prostate cancer (PCa) and its role in predicting aggressive tumor behavior and disease progression is largely unexplored. The study explores the PCa TME through the characterization of cancer-associated fibroblasts (CAFs) using both immunohistochemistry (IHC) and genomics approaches. This is then correlated with transrectal ultrasound shear wave elastography (USWE)-measured tissue stiffness.

Patients and Methods: Thirty patients with clinically localized PCAs undergoing radical prostatectomy for different risk categories of tumor (low, intermediate, and high) defined by Gleason score (GS) were prospectively recruited into this study. Prostatic tissue stiffness was measured using USWE prior to surgery. The CAFs within the TME were identified by IHC using a panel of six antibodies (FAP, SMA, FSP1, CD36, PDGFRα, and PDGFRβ) as well as gene expression profiling using TempO-sequence analysis. Whether the pattern and degree of immunohistochemical positivity (measured by Quick score method) and expression of genes characterizing CAFs were correlated with USWE- and GS-measured tissue stiffnesses were tested using Spearman’s rank correlation and Pearson correlation.

Results: There was a statistically significant correlation between GS of cancers, the pattern of staining for CAFs by immunohistochemical staining, and tissue stiffness...
measured in kPa using USWE (p < 0.001). Significant differences were also observed in immunohistochemical staining patterns between normal prostate and prostatic cancerous tissue. PDGFRβ and SMAα immunostaining scores increased linearly with increasing the USWE stiffness and the GS of PCa. There was a significant positive correlation between increasing tissue stiffness in tumor stroma and SMAα and PDGFRβ gene expression in the fibromuscular stroma (p < 0.001).

**Conclusion:** USWE-measured tissue stiffness correlates with increased SMAα and PDGFRβ expressing CAFs and PCa GSs. This mechanistic correlation could be used for predicting the upgrading of GS from biopsies to radical surgery and response to novel treatments.

**Keywords:** cancer-associated fibroblasts, prostate cancer, immunohistochemistry, stiffness, tumor microenvironment

**KEY POINTS:**

1. There is heterogeneity in the amount and types of CAFs in the TME of localized PCa and this correlates with tissue stiffness (elastography) on imaging.
2. Immunohistochemical expression of SMAα by CAFs also correlates with GS of PCa and was significantly different from normal benign prostate tissue.
3. USWE-measured tissue stiffness imaging provides an insight into TME and the presence of CAFs in localized PCa.

**1 INTRODUCTION**

Several studies indicate that the biophysical and biochemical features of the connective tissue stroma within the normal prostate are different from those of the tumor and that the properties of the tumor stromal elements have a significant impact on cancer development and progression (1–4). Similar to other cancers, prostate cancer (PCa) is not now seen simply as a disease of abnormally proliferating epithelial cells, but rather as diverse diseases arising from the complex interactions between the cells of the prostatic epithelial compartment and the surrounding stromal environment in which they sit (5). PCa has a high degree of heterogeneity in tumor genotype, phenotype, and behavior (including responsiveness to therapy) between tumors of the same histological type in different patients.

There is a cross-talk between cell types within the tumor microenvironment (TME) where one of the most important and abundant cell types is the CAFs (5). CAFs form the largest population of stromal cells in TME (6) and have been found to induce an alteration in the architecture and physical properties of the ECM that promote cell migration, invasion, and tumor growth (7). Vimentin and FSP1 are expressed by normal fibroblasts embedded in the fibrillar ECM of connective tissue (8) but CAFs can be identified by altered or overexpression of a number of molecular markers that are upregulated compared to normal fibroblasts, including α-smooth muscle actin (SMAα), fibroblast activation protein (FAP), fibroblast specific protein-1 (FSP-1), platelet-derived growth factor receptor-α (PDGFR-α), and platelet-derived growth factor receptor-β (PDGFR-β) (9, 10). Several studies have noted specifically that CAFs can be distinguished by their expression of SMAα (11–13). FAP has also emerged as a potential candidate for directly targeting CAFs (14) as it may be expressed by activated fibroblasts within tumor stroma and healing wound tissue. It is not expressed by mature somatic tissue fibroblasts (15).

The activity of the CAF remodeling is associated with increased tissue stiffness and altered mechanical stress responses (16); several studies discovered that the mechanical characteristics of prostate tissue revealed an increased stiffness within the cancerous stroma compared to the normal stroma (17–19). Our group and others have reported that USWE characterization of tissue stiffness of PCa can be considered as a promising imaging method or technique; previous studies have shown that this parameter correlated with the GS, identifying clinically significant PCa (20–25) with diagnostic accuracy, evident by reported sensitivity, specificity, positive predictive value, and negative predictive values (23, 26, 27).

In the present study, we explored the correlation between CAF heterogeneity within TME and transrectal USWE-measured tissue stiffness. CAF heterogeneity was explored using immunohistochemistry and gene expression. The specific selection of these two methods was based on the understanding that these are complementary technology and would provide reasonable assurance and validity to study findings. Gene expression technique used TempO-Seq assays specifically designed for the study of RNA expression in a formalin-fixed tissue specimen. Knowledge gained through this study could establish or otherwise invalidate the role of non-invasive imaging as a marker of changes in TME and potentially improve prediction of upgrading from biopsy to radical surgery and also facilitate risk stratification of patients with localized PCa. Moreover, differences in the TME (including immune cell infiltration, CAFs, the density of the extracellular matrix, hypoxia, and interstitial fluid pressure) can explain why tumors behave differently to the same treatment modalities.
2 PATIENTS AND METHODS

2.1 Study Design and Patients

This was a prospective, protocol-driven study with ethical approval through East of Scotland Ethical committee, approval from the Tayside Tissue Bank, University of Dundee, Ninewells Hospital and Medical School (Dundee, UK) to undertake investigations on patient specimens, and Caldicott permission (IGTCAL5626) to access patient follow-up data.

Consecutive men with localized PCa undergoing radical surgery were recruited. Pre-operative elastograms of prostate glands were obtained using transrectal USWE. Prostatic tissue stiffness in kilopascals (kPa) prior to radical surgery was measured in all the participants (Figure 1). Patients with prior prostatic surgery or radiotherapy or in whom there had been previous rectal surgery precluding placement of transrectal ultrasound examination were excluded. Patient-specific customized 3D molds were printed using imaging and 3-D printers in all the cases according to our published protocol (28).

The histopathology of the cancers within the radical surgery specimens was assessed and graded by an experienced uropathologist (JW). The same pathologist had also assessed GS of biopsy in these men. The 30 patients recruited into the study were classified into low-, intermediate-, and high-risk categories according to Gleason grading that was undertaken according to standard diagnostic criteria. Low-risk cases were of GS 3 + 3 \( (n = 3) \), intermediate-risk GS cases were those with a GS of 3 + 4 \( (n = 13) \), and high-risk cases were of GS 4 + 3 and higher \( (n = 14) \). Representative blocks of the tumor were selected for subsequent immunohistochemical and gene expression studies. These men were followed by protocol-based interval PSA. Any biochemical recurrence (PSA > 0.2) was recorded. We also calculated upgrading/downgrading of GS from biopsies to radical surgery in this cohort.

2.2 Ultrasound Shear Wave Elastography

Transrectal image acquisition for USWE was performed by using a sonographic push pulse to generate shear waves. A dynamic map of tissue stiffness (described as a Young's Modulus) reflected as a different speed of shear waves in each tissue area in real time (29, 30) was obtained. Details of USWE have been described by us and others in previous publications (24, 31, 32). The prostate was subjected to the minimum possible pressure while remaining in contact with the probe for 5 to 10 s to ensure a stable acquisition of images. All USWE images were taken with a transrectal endocavitory transducer (SuperSonic imaging, Aix en Provence, France) with patients in lateral or lithotomy positions. USWE mode was used and elastograms of the prostate were acquired for each prostate lobe from cranial to caudal direction. Because the USWE field of view was insufficient to assess the whole prostate, the right and left lobes were scanned individually. The USWE images were obtained in transverse planes using a slow movement that allowed stabilization of the signals with gaps of 4 to 6 mm from base to apex. The most suspected lesions in planes were rescanned in 2- to 3-mm gaps. These suspicious locations were also inspected by rotating transducers in different directions to confirm abnormalities and estimate their sizes. The most suspect planes containing cancer were labeled and reconstructed offline into 3D images. Images (from red to blue for high to low stiffness, respectively) for each region were digitally saved, and the stiffness was quantitatively measured. The ratio between abnormal and normal regions was also measured. The images of the participants were then utilized to create specific prostate molds, which were used to guide prostate slicing postoperatively. A qualified urologist with more than 10 years of experience in transrectal ultrasound conducted the USWE. Based on data from the same study (31), we categorized tissue stiffness into <50, 50–100, 101–150, 151–200, 201–250, and 251–300. The person
in charge of ultrasound and responsible for categorization was not aware of immunohistochemistry and gene expression results.

2.3 Immunohistochemistry

Sections from a representative block of the tumor were processed for immunohistochemical studies to identify CAFs. A panel of six antibodies (FAP, SMAα, FSP-1, CD36, PDGFR-α, and PDGFR-β) was utilized to screen tissue sections for CAFs in normal and neoplastic tissue. Antigen retrieval and de-paraffinization were performed using DAKO EnVision™ FLEX Target Retrieval solution (high pH) (Agilent Technologies) buffer in a DAKO PT Link. Sections were blocked in EnVision™ FLEX Peroxidase-Blocking reagent for 5 min at room temperature and incubated overnight at 4°C with anti-Alpha Smooth Muscle Actin (cat # NCL-L-SMA, Leica Biosystems) at a dilution of 1:50, anti-CD36 [C1C3] (cat no. GTX100642, GeneTex, Inc) at a dilution of 1:250, anti-FAP [JA56-11] (cat # MA5-32407, ThermoFisher Scientific) at a dilution of 1:100, anti-PDGFRα [D1E1] (#3174, Cell Signaling Technology) at a dilution of 1:100, anti-PDGFRβ [SY10-08] (cat # MA5-32407, ThermoFisher Scientific) at a dilution of 1:100, and S100A4 [EPR14639(2)] (cat # ab220213, abcam) at a dilution of 1:5,000. Immunostaining using DAKO EnVision™ FLEX system (Agilent Technologies) on a DAKO Autostainer Link 48 was carried out according to the manufacturer’s protocol; more details are presented in Table 1. DAKO substrate working solution was used as a chromogenic agent for 2 × 5 min and sections were counterstained with EnVision™ FLEX hematoxylin. Sections known to stain positively were included in each batch and negative controls were prepared by replacing the primary antibody with DAKO antibody diluent. The “Quick” score method of assessment was used to determine the range of immunostaining performed. In this method, the intensity of the immunohistochemical reaction that was seen through the microscope was recorded as follows: 0, negative (no staining of any nuclei even at high magnification); 1, weak (only visible at high magnification); 2, moderate (visible at low magnification); and 3, strong (strikingly positive even at low magnification). The percentage of tumor nuclei that stained positively was also reported as 0 (none); 1 (approximately 1%–25%); 2 (26%–50%); 3 (51%–75%); or 4 (76%–100%). The intensity score was added to the proportion score to give the Quick score, which ranged from 0 to 7 for each tumor (33, 34).

2.4 Gene Expression

In this study, we used TempO-Seq assays (BioSpyder, Inc. BIOCRAVIS, LTD, Biotechnology company in Glasgow, Scotland) to target sequencing-based RNA expression analysis on FFPE tissue sections of the human prostate. From each case, an area of 10 mm² was dissected from normal and malignant prostate tissue and submitted for analysis. Each area was dissected using fresh blades to avoid cross-contamination of the tissue samples. The samples were collected into sterile Eppendorf tubes and were then analyzed using appropriate internal process controls (BioClavis) as well as with the Human Whole Transcriptome v2.0 panel with standard attenuators.

2.4.1 TempO-Seq Assay Protocol Summary

Sequencing libraries for targeted panels were generated as illustrated in Figure 2.

In TempO-Seq, each Detector Oligo comprises a sequence complementary to an mRNA target plus a universal (i.e., same for every targeted gene) primer binding site. They anneal in immediate juxtaposition to each other on the targeted RNA template such that they can be ligated together. Then, the ligated detector oligos are PCR-amplified using a primer set (single-plex PCR reaction, with a single primer pair for each sample) that introduces both the adaptors required for sequencing and a sample-specific barcode. The barcode sequences flank the target sequence and are appropriately inserted into the standard Illumina adaptors to permit standard dual-index sequencing of the barcodes and deconvolution of sample-specific reads from the sequencing data using the standard Illumina software. All the PCR-amplified and barcoded samples are combined into a single library for sequencing. Sequencing reads are de-multiplexed using the standard sequencing instrument software for each sample using the barcodes to give a FASTQ file for each. The genes of interest, which are PDGFRα, PDGFRβ, CD36, FSP1, FAP, and SMAα, were identified for further analysis.

2.5 Data Analysis

SPSS v.22 (SPSS, Chicago, IL, USA) was used for all statistical analyses. The following data were collected: Patient’s age (in years), prostate-specific antigen (PSA, in ng/ml), prostate volume (in ml), modulins measurement using USWE (in kPa), Gleason score (GS), and immunostaining “Quick” score (in a scale of 0-7) as well as gene expression for the six genes of interest (PDGFRα, PDGFRβ, CD36, FSP1, FAP, and SMAα). Continuous data were first tested to see if they were normally distributed by the Kolmogorov-Smirnov Test of Normality. The mean (m) and standard deviation (SD) were described if the variable followed a normal distribution. The median (M) and interquartile range (IQR) were presented if the variable did not follow a normal

| Antibody | Catalogue # | Company | Type | Tissue Control | Dilution |
|----------|-------------|---------|------|----------------|----------|
| CD36 (C1C3) | GTX100642 | Genetex | Poly Rabbit | Kidney | 1/250 |
| FAP (JA56-11) | MA5-32670 | Invitrogen | Mono Rabbit | Testis | 1/100 |
| FSP-1 (S100A4) | Ab220213 | Abcam | Mono Rabbit | Gastric Ca | 1/5000 |
| PDGFRα (D1E1) | #3174 | Cell Signaling | Mono Rabbit | GIST | 1/100 + L |
| PDGFRβ (SY10-08) | MA5-32047 | Invitrogen | Mono Rabbit | Spleen | 1/100 |
| SMA Alpha | NCL-L-SMA | Leica | Mono Mouse | Small bowel | 1/50 + L |
distribution. In this study, a GS $\geq 4 + 3$ was considered to be significant PCa following the UCL 2 definition. A Spearman rank correlation was conducted to examine the relationship between GS of radical prostatectomy and tissue stiffness (in kPa) using USWE. Correlations between cancer and normal stroma of IHC and gene expression were analyzed using Spearman’s rank correlation and Pearson correlation. A $p$-value of 0.01 was considered to be statistically significant in correlation procedures.

3 RESULTS

The clinicopathological data of the cohort are presented in Table 2. Thirty patients with a mean age of 67.8 (SD, 5.4) years were treated by radical prostatectomy with a median PSA level of 9.7 (IQR, 17.5–7.9) ng/ml and a mean prostate volume of 64.2 (SD, 32.9) ml.

In this study, there was a positive correlation between USWE-measured tissue stiffness and GS in medium strength, which is statistically significantly measured by Spearman rank correlation ($r_s = 0.67$, $p < 0.001$, df = 28). Tissue stiffness increased with GS.

3.1 Correlation Between Tissue Stiffness and Immunohistochemistry

Representative whole slides from each of the radical prostatectomy specimens were stained using the six antibodies to detect the CAFs and the Quick score method was used for scoring the staining intensity in normal and cancer tissue. For FAP and PDGFR$\alpha$, weak staining was observed in the fibromuscular stroma compared to the positively stained regions in the tumor epithelium (Figures 3A-E). The correlation between increasing the tissue stiffness and expression of FAP and PDGFR$\alpha$ in the fibromuscular stroma was not significant as presented in Figures 4C, D. For SMA$\alpha$, the intensity and density of staining were scored. Strong staining was observed in the fibromuscular stroma compared to the negatively stained in normal epithelium. SMA$\alpha$ was expressed at a higher level in the high-grade cancers [GS (4 + 5)] compared to the lesser grade PCa as shown in Figure 3B. There was a significant strong positive correlation between tissue stiffness and SMA$\alpha$ expression in terms of IHC score in the fibromuscular stroma [$r_s(28) = 0.909$, $p < 0.001$] as presented in Figure 4B. Also, PDGFR$\beta$ was strongly expressed in the fibromuscular stroma and was expressed at a higher level in the high-grade PCa compared to lower grade PCa similar to SMA$\alpha$ as presented in Figure 3F. Similar to SMA$\alpha$, there was a significant strong positive correlation between increasing tissue stiffness and PDGFR$\beta$ expression in terms of IHC score in the fibromuscular stroma [$r_s(28) = 0.925$, $p < 0.001$] as shown in Figure 4E. The Spearman rank correlation results

| Patient characteristic | No. (%)|
|------------------------|-------|
| No. Pts                | 30    |
| Age (in years)         | 67.8 ± 5.4 |
| PSA level (ng/ml)      | 9.7 (17.5–7.9) |
| Prostate volume        | 64.2 ± 32.9 |
| Stiffness measurement using USWE in kilopascals (mean ± SD) | No. (%) |
| <50                    | 0 (0.0)|
| 50–100                 | 4 (13.3)|
| 101–150                | 20 (66.7)|
| 151–200                | 5 (16.7)|
| 201–250                | 0 (0)|
| 251–300                | 1 (3.3)|
| Gleason Score          | No. (%)|
| 3+3                    | 3 (10.0)|
| 3+4                    | 13 (43.3)|
| 4+3                    | 5 (16.7)|
| 3+5                    | 4 (13.3)|
| 4+5 or greater         | 5 (16.7)|
also showed a significant strong positive correlation between GS increase and the increase of SMA α [rs(28) = 0.912, p < 0.001] and PDGFRβ [rs(28) = 0.925, p < 0.001] expression in terms of IHC score, respectively.

For FSP1, the intensity of staining was scored high in tumor fibromuscular stroma compared to the negatively stained epithelium. When comparing intermediate-grade PCa to low- and high-grade PCa, strong staining was observed in the cancerous fibromuscular stroma as shown in Figure 3C. There was no significant correlation between increasing the tissue stiffness and expression of FSP1 in the fibromuscular stroma as shown in Figure 4A.

For CD36, there was no expression of staining in both tumor and fibromuscular stroma compared to the positively stained normal epithelium as presented in Figure 3D. Table 3 shows the evaluation and calculation of the average pixel intensity and the
percentage of the positive staining pattern of the IHC images of the six antibodies using ImageJ.

### 3.2 Correlation Between Tissue Stiffness and Gene Expression

The results of the gene expression for PDGFRα showed a bimodal pattern. The expression was low in GS 3 + 3 and 4 + 5 cancer stroma compared to the normal stroma. However, for 3 + 5, 3 + 4, and 4 + 3 GS cancers, the gene expression is higher in cancer stroma than normal stroma. FSP1 and FAP have little expression in both normal and cancer stroma in all GS cancers. CD36 has no expression in all GS. Conversely, SMAα and PDGFRβ have the best gene expression results supporting the IHC results, and the gene expression increased gradually with an increase in the GS as presented in Figure 5. There was a significant positive correlation between SMAα and PDGFRβ gene expression in the fibromuscular stroma and GS [r_s(28) = 0.882, p < 0.001, and r_s(28) = 0.881, p < 0.001, respectively]. When evaluating the relationship between gene expression of SMAα and PDGFRβ and tissue stiffness in the tumor stroma, Pearson correlation results showed a significant positive correlation between SMAα [r(28) = 0.706, p < 0.001] and

---

**TABLE 3** | Using ImageJ to evaluate and calculate the average pixel intensity and the percentage of the positive staining pattern of the IHC images.

| Antibody | Gleason score | Area         | Staining area % | The mean of staining area | Location of staining (nuclei or fibromuscular stroma) |
|----------|---------------|--------------|-----------------|---------------------------|------------------------------------------------------|
| FAP      | 3+3           | 4194304      | 9.8             | 7.9                       | Nuclei                                               |
|          | 3+4           | 4194304      | 2.1             | 17.5                      | Nuclei                                               |
|          | 4+3           | 4194304      | 4.5             | 18.3                      | Nuclei                                               |
|          | 3+5           | 4194304      | 15.7            | 44.5                      | Nuclei                                               |
|          | 4+4           | 4194304      | 15.4            | 56.0                      | Nuclei                                               |
| SMAα     | 3+3           | 4194304      | 5.1             | 9.2                       | Fibromuscular stroma                                 |
|          | 3+4           | 4194304      | 7.7             | 19.4                      | Fibromuscular stroma                                 |
|          | 4+3           | 4194304      | 16.7            | 35.3                      | Fibromuscular stroma                                 |
|          | 3+5           | 4194304      | 21.7            | 40.1                      | Fibromuscular stroma                                 |
|          | 4+4           | 4194304      | 25.7            | 45.1                      | Fibromuscular stroma                                 |
| FSP1     | 3+3           | 4194304      | 6.9             | 6.6                       | Fibromuscular stroma                                 |
|          | 3+4           | 4194304      | 8.8             | 8.4                       | Fibromuscular stroma                                 |
|          | 4+3           | 4194304      | 8.7             | 16.9                      | Fibromuscular stroma                                 |
|          | 3+5           | 4194304      | 9.6             | 25.4                      | Fibromuscular stroma                                 |
|          | 4+4           | 4194304      | 9.7             | 21.9                      | Fibromuscular stroma                                 |
|          | 4+5           | 4194304      | 25.7            | 45.1                      | Fibromuscular stroma                                 |
| CD36     | 3+3           | 4194304      | 0.7             | 2.4                       | Nuclei                                               |
|          | 3+4           | 4194304      | 2.8             | 18.4                      | Nuclei                                               |
|          | 4+3           | 4194304      | 2.2             | 7.5                       | Nuclei                                               |
|          | 4+4           | 4194304      | 14.6            | 35.2                      | Nuclei                                               |
|          | 4+5           | 4194304      | 0.7             | 0.8                       | Nuclei                                               |
| PDGFRα   | 3+3           | 4194304      | 0.5             | 2.6                       | Nuclei                                               |
|          | 3+4           | 4194304      | 7.9             | 26.4                      | Both                                                 |
|          | 4+3           | 4194304      | 14.3            | 26.6                      | Both                                                 |
|          | 3+5           | 4194304      | 11.5            | 44.1                      | Both                                                 |
|          | 4+4           | 4194304      | 12.5            | 44.7                      | Both                                                 |
|          | 4+5           | 4194304      | 12.5            | 44.7                      | Both                                                 |
| PDGFRβ   | 3+3           | 4194304      | 1.4             | 3.9                       | Fibromuscular stroma                                 |
|          | 3+4           | 4194304      | 8.3             | 30.3                      | Fibromuscular stroma                                 |
|          | 4+3           | 4194304      | 11.3            | 39.3                      | Fibromuscular stroma                                 |
|          | 4+4           | 4194304      | 15.8            | 59.0                      | Fibromuscular stroma                                 |
|          | 4+5           | 4194304      | 25.4            | 96.5                      | Fibromuscular stroma                                 |

---

**FIGURE 5** | The scatter plots show the relationship between the Gleason score and the gene expression of the SMAα and PDGFRβ [r_s(28) = 0.58, p = 0.001, and r_s(28) = 0.56, p = 0.001], respectively.
PDGFRβ \( \tau(28) = 0.809, \ p < 0.001 \) gene expression in the fibromuscular stroma and increasing tissue stiffness.

### 4 DISCUSSION

The present study explored the mechanistic and immunohistochemical features of the extracellular matrix of PCa of varying GSs in comparison to normal benign prostate tissue. The results were validated using a novel TempO-sequence assay gene expression methodology. We have focused on both quantitative imaging of the tumors and their microenvironment, thus providing a comprehensive insight into the PCa disease microenvironment.

In a heterogeneous disease such as PCa, research needs to focus on understanding cellular architecture including TME in order to accurately predict the behavior of cancer including the development of metastatic disease. The study used different modes of analysis, including genomic sequencing, USWE, and IHC to characterize tumor heterogeneity and TME. A comprehensive tumor characterization can lead to an increased understanding of the risk stratification of PCa for precise diagnosis and treatment. TME characterization using three different modalities improved our ability to predict more aggressive cancers and their outcomes. There have been no investigations to date of tissue-level spatial heterogeneity in CAFs in PCa TME and how they relate to the radiological appearance of these tumors on USWE-measured quantitative tissue stiffness. Multiscale characterization, such as that carried out in the present study, provides identification of quantitative metrics derived from non-invasive imaging, i.e., USWE, which correlate with or predict aggressive PCa phenotypes. These metrics may be made available to physicians making decisions for new patients with biopsy confirmed PCa to choose the best therapeutic option based on the presence of certain TME characteristics that may affect treatment response or outcome.

The multimodal and multiscale investigative workflow used in our study provides a new option for RNA extraction of formalin-fixed tissues using a TempO-sequence platform in PCa for next-generation sequencing and genomic analysis. Again, to our knowledge, this has not been reported. The technique may be useful to get information from archived tissues with long-term follow-up of patient cohorts.

We observed a consistent and coherent pattern of increased GS correlating with increased tissue stiffness on USWE and increased expression of SMAα and PDGFRβ both on IHC and genomics analysis. The workflow also suggested that genomics expression for SMAα and PDGFRβ along with measurement of stiffness using USWE could narrow the discrepancy gap between histopathology of biopsies and radical surgery (Figure 6). A better prediction of aggressive cancer phenotype would improve risk stratification and treatment strategies. Use of biomarkers, both genomics and immunohistochemistry, to risk stratify PCa would require validation of our results in a larger cohort of men using multicenter data. We envisage that the findings of the study would act as a driver to change clinical practice, especially in men where biopsy has under-sampled PCa and/or does not correlate with the rise in PSA level or the findings of multi-parametric MRI.

In this study, a panel of six antibodies showed some staining heterogeneity in the fibromuscular stroma. However, some of those markers were difficult to interpret, but PDGFRβ and SMAα are the two antibodies that gave crisp and strong staining of the CAFs and the intensity of the staining significantly increased with increasing the USWE-measured stiffness and GS of PCa. In corroboration of our findings, Yngve et al. found the mean expression of PDGFRβ to be higher in tumor stroma compared to the normal stroma (35). Masko et al. found that the metastasis breast stroma has higher SMAα expression compared to the normal stroma (36). According to some studies, higher SMAα expression in stromal cells correlates with tumor aggressiveness, progression,
and worse prognosis (37, 38). To confirm the IHC result, a gene expression was carried out for the six antibodies. The results validated and supported the results of the IHC of the SMAα and PDGFRβ.

A comprehensive illustration of TME and measurement of stiffness may allow us to understand mechanosensing, which influences directional cell migration. The mechanosensing mechanisms of cancer cells change the growth factor signalling of cells including secretion of proteolytic enzymes, which degrade the fiber matrix of cancers. Some of these changes may explain enhanced growth, survival, and invasion/metastases of tumors. Increased tumor tissue stiffness has been associated with a higher risk of biochemical recurrences following radical treatment of localized PCa (32). Previous studies have linked tumor tissue stiffness to cancer progression, stem cell differentiation, and expression of genes involved in invasion and metastasis; thus, mechanistic insights and CAF heterogeneity from our study might explain part of this (39, 40). Interestingly, Nordby et al. have reported high expression of PDGFRβ to be an independent prognostic marker on multivariate regression analysis for clinical and biochemical recurrence of men following treatment for localized disease (35).

There are several clinical implications of the present study. The findings should make us look at cancer as a disorder in the local microenvironment rather than a disease confined to cells alone. A positive correlation between CAF heterogeneity and stiffness on USWE provides us a non-invasive way to image the cancer microenvironment. This opens us to a new area that has prognostic and therapy monitoring prospects in novel treatments such as extracorporeal shock waves (41). PCa is a clinically and molecularly heterogeneous disease and we need better prognostic biomarkers for risk stratification of patients for various treatment options.

The second use of these findings could help us in narrowing the gap of GS upgrading between biopsies and radical surgery. GS of PCa on diagnostic biopsies is known to get upgraded following radical prostatectomy histopathology. The upgrade rate of biopsy GS on radical prostatectomy is about 35.5% (range: 14%–51%) (42). This remains a crucial challenge to overcome, in particular when this is utilized for risk assessment in men with a recent PCa diagnosis (43). We found increased expression of SMAα and PDGFRβ in ECM around tumors correlated with GS in radical prostatectomy histopathology in our study. Whether expression of these markers in biopsies would predict upgrading of GS needs further study; however, our previously reported results indicated a significant advantage of using USWE as predicting and detecting technique for PCa grade (32), and it would impact the choice of therapeutic approach and management of PCa.

There were some limitations in this study. First, we did not investigate the organization of the collagen types that were produced by CAFs and the disorder of the fibers in the tumors. However, this study aimed to distinguish the different elasticities of PCa using IHC. In a recently published study (44), we have investigated the collagen types and orientation in causing tissue cancer stiffness. Another limitation is that this study is from a single institution with an experienced operator performing the test, most certainly USWE.

Findings from the present study should add to further knowledge on the mechanism of PCa disease. This will also add and open future avenues for designing PCa therapeutics and interventions including focal therapy.

**CONCLUSION**

USWE-measured tissue stiffness correlates with the degree of CAF heterogeneity of TME on the immunohistochemical characterization of localized PCa. Expression of SMAα and PDGFRβ is strong in TME and correlates with USWE tissue stiffness.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article supplementary materials. Further inquiries can be directed to the corresponding author.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by East of Scotland ethics committee. The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

Conceptualization: GN and CL. Methodology: WA, XZ, CO, SB, NK, JW, CL and GN. Investigation: WA, XZ, CO, SB, NK, JW, CL, and GN. Writing—original draft: WA and GN. Reviewing and editing: WA, XZ, CO, SB, NK, JW, CL, and GN. Supervision: GN and CL. All authors have read and agreed to the published version of the manuscript.

1. Morrison C, Thornhill J, Gaffney E. The Connective Tissue Framework in the Normal Prostate, B.P.H and Prostate Cancer: Analysis by Scanning Electron Microscopy After Cellular Digestion. *Urol Res* (2000) 28:304–7. doi: 10.1007/s002400000123

2. Tuxhorn JA, Ayala GE, Rowley DR. Reactive Stroma in Prostate Cancer Progression. *J Urol* (2001) 166:2472–83. doi: 10.1016/S0022-5347(05)65620-0

3. Tuxhorn JA, Ayala GE, Smith MJ, Smith VC, Dang TD, Rowley DR. Reactive Stroma in Human Prostate Cancer: Induction of Myofibroblast Phenotype and Extracellular Matrix Remodeling. *Clin Cancer Res* (2002) 8:2912–23.
20. Ling Y, Roweley DR. The Reactive Stroma Microenvironment and Prostate Cancer Progression. Endocr Relat Cancer (2012) 19:187–204. doi: 10.1016/j.e拙le0.2012.02.004
21. Chiarugi P, Paoli P, Cirri P. Tumor Microenvironment and Metabolism in Prostate Cancer. Semin Oncol (2014) 41:267–80. doi: 10.1053/j.smoncol.2014.03.004
22. Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell (2011) 144:646–74. doi: 10.1016/j.cell.2011.02.013
23. Jolly LA, Novitskiy S, Owens P, Massoli N, Cheng N, Fang W, et al. Fibroblast-Mediated Collagen Remodeling Within the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E and Pten Loss. Cancer Res (2016) 76:1804–13. doi: 10.1158/0008-5472.CAN-15-2351
24. Kalluri R, Zeisberg M. Fibroblasts in Cancer. Nat Rev Cancer (2006) 6:392–401. doi: 10.1038/nrc1787
25. Gascard P, Tlsty TD. Carcinoma-Associated Fibroblasts: Orchestrating the Composition of Malignancy. Genes Dev (2016) 30:1002–19. doi: 10.1101/gad.279737.116
26. Öhlund D, Elyada E, Tuveson D. The Reactive Stroma Microenvironment and Metabolism in Prostate Cancer: Diagnostic, Vol. 275. Paris, France (2015).
27. Woo S, Kim SY, Cho JY, Kim SH. Shear Wave Elastography Assessment in the Prostate: An Intraobserver Reproducibility Study. Clin Imaging (2019) 30:97–7. doi: 10.1016/j.clinimag.2014.11.013
28. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
29. Barnes DM, Harris WH, Smith P, Millis RR, Rubens RD. Immunohistochemical Determination of Oestrogen Receptor: Comparison of Different Methods of Assessment of Staining and Correlation With Clinical Outcome of Breast Cancer Patients. Br J Cancer (1996) 74:1445–51. doi: 10.1038/1bc.1996.563
30. Nordby E, Richardsen E, Rakae M, Mess N, Donnem T, Patel HH, et al. High Expression of PDGFR-β in Prostate Cancer Stroma is Independently Associated With Clinical and Biochemical Prostate Cancer Recurrence. Sci Rep (2017) 7:1–9. doi: 10.1038/s41598-017-00169-7
31. Yamashita M, Ogawa T, Zhang X, Hanamura N, Kashiura Y, Takamura M, et al. Role of Stromal Myofibroblasts in Invasive Breast Cancer: Stromal Expression of Alpha-Smooth Muscle Actin Correlates With Worse Clinical Outcome. Breast Cancer (2012) 19:170–7. doi: 10.1007/s12282-010-0234-5
32. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
33. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
34. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
35. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
36. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
37. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
38. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
39. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
40. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
41. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
42. Reiner A, Neumeister B, Reiner G, Schemper M, Jakesz R, Spona J. Immunocytochemical Localization of Estrogen and Progesterone Receptor and Prognosis in Human Primary Breast Cancer. Cancer Res (1990) 50:7507–61.
44. Ageeli W, Zhang X, Ogbonnaya CN, Ling Y, Wilson J, Li C NG. Characterisation of Collagen Re-Modelling in Localised Prostate Cancer Using Second-Generation Harmonic Imaging and Transrectal Ultrasound Shear Wave Elastography. Dundee, Scotland, UK (2021).

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Ageeli, Zhang, Ogbonnaya, Bray, Kernohan, Wilson, Li and Nabi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.